Global pharma major Dr. Reddy’s Laboratories Limited has informed BSE today that it has launched Moxifloxacin Hydrochloride tablets in the US market on March 4, 2014 following approval from US Food and Drug Administration (USFDA).

The tablets of 400 mg are equivalent to generic version of Avelox (moxifloxacin HCL) in the US market according to the disclosure. Avelox has clocked about $195 million annual sales ending the calendar year 2013 according to IMS Health.

Dr. Reddy’s Moxifloxacin Hydrochloride Tablets are available in bottle counts of 30.